Abstract 2259P
Background
Type I polarized macrophages (M1) play an anti-tumor role in the tumor microenvironment (TME), and more M1 infiltration means better prognosis. Previous studies have developed algorithms to predict the fraction of M1 based on transcriptomic data, whereas few study focus on DNA methylation data.
Methods
A macrophage multiplex immunofluorescence (mIF) panel (including DAPI, panCK, CD68, CD86, IRF5, CD163 and CD206) and DNA methylation sequencing were used in lung adenocarcinoma (LUAD) patients’ formalin-fixed paraffin-embedded samples. The fraction of M1 (with more positive M1 markers [CD86 and IRF5] than M2 markers [CD163 and CD206]) was calculated based on all macrophages (DAPI+panCK-CD68+). Patients were randomly divided into training cohort (70%) and test cohort (30%). The Pearson correlation and random forest algorithm were used to screened genes to build artificial neural network (ANN) models in the training cohort. Three hundred times of three-fold cross validation were performed to obtain 900 ANN models and test the accuracy of them. The final predicted value of the ANN system were equal to the weighted average of output values of all 900 ANN models. Finally, the accuracy of the ANN system was tested validated in the test cohort.
Results
Forty patients with LUAD were enrolled, and the median fraction of M1 was 3.27% (range: 0% to 30.91%). A total of 43 genes were with p-value < 0.001 were selected by Pearson correlation, and the top eight genes (C10orf90, ITGAX, TMED9, RGN, CENPF, LGI4, PPCS and KIAA1211) from random forest algorithm were used to build 900 three-layer ANN models. Each ANN model had eight input nodes, five hidden nodes and one output node. The frequency of ANN model whose weight > 0.70 (the accuracy > 0.70) was 74.78% (673/900). The Pearson correlation coefficient between the predicted value and the true M1 fraction was 0.89 (R2 = 0.79, p < 0.01) in the training cohort and 0.80 (R2 = 0.65, p < 0.01) in the test cohort.
Conclusions
DNA methylation data is more suitable to establish models than RNA data. In this study, an ANN system based on DNA methylation data was constructed and showed a potential value in predicting the fraction of M1 in LUAD, which could help to further understand the TME and identify patients that would benefit from immunotherapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2274P - Deep learning-based prediction of pathologic complete response to neoadjuvant therapy in breast cancer using H&E images and RNA-Seq in the IMMUcan study
Presenter: Christian Esposito
Session: Poster session 08
2275P - Circulating leptin and adiponectin levels in premenopausal women with and without breast cancer (BC) and a body mass index (BMI) ≥25 kg/m2
Presenter: Isabel Calvo
Session: Poster session 08
2276P - Regulation of major histocompatibility class-I gene methylation using DNA methyltransferase inhibitor and PD-L1 inhibitor in triple-negative breast cancer
Presenter: Young Ju Jeong
Session: Poster session 08
2277P - A colorimetric biosensor to track Trop-2 status of tumor cells for diagnosis of breast cancer
Presenter: Tianyu Zeng
Session: Poster session 08
2278P - Endothelial cell heterogeneity defined by single-cell spatial transcriptomic analysis of breast cancers
Presenter: Krisztian Homicsko
Session: Poster session 08
2279P - Glucocorticoid receptor antagonism and beta adrenergic receptor inhibition: Implications in triple-negative breast cancer brain metastasis
Presenter: Andra Antohi
Session: Poster session 08
2280P - MiR-193a-3p: A pan-repressor of H2S synthesizing enzymes regulates tumorigenesis and immunosurveillance in breast cancer
Presenter: Alyaa Dawoud
Session: Poster session 08
2281P - Multi-omics evaluation of TFE3-fusions and potential association with immuno-metabolic vulnerabilities in alveolar soft part sarcoma (ASPS) and translocation-positive renal cell carcinoma (tRCC)
Presenter: Shuanzeng Wei
Session: Poster session 08
2282P - Tissue glycan profiling in predicting immunotherapy response in renal cell carcinoma and hepatocelllular carcinoma
Presenter: Qin Jian Low
Session: Poster session 08
2283P - Assessing the replicative potential of the oncolytic virus VSV-GP in patient-derived tumor biopsies ex vivo
Presenter: Benjamin Schoeps
Session: Poster session 08